Abstract:The human-derived tumor xenografts (PDX) model can retain the original tumor heterogeneity and the microenvironment of tumor growth. It has a high degree of similarity with the patient's tumor tissue in histopathology and molecular phenotype, which can reflect the patient's clinical outcomes very well, more accurately predict the clinical efficacy of new drugs, and provide a reliable preclinical model for patients with urinary tract tumors including renal carcinoma, bladder cancer, and prostate cancer, especially for the study of drug-resistant relapse and metastatic tumors after clinical treatment. The PDX model is of great significance in the application of new drug development, biomarker screening, personalized treatment, and so on, which has laid the foundation for the research of urological tumor precision medicine and translational medicine. This article has reviewed the progress in the construction and application of PDX model in urological tumors.
